Time to End "Manels" in Clinical Trial Leadership.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Representation and career trajectories of female principal investigators in clinical trials, 2010-2023.Contemporary clinical trials communications · 2025
   Article
2. Social Media and Cardiovascular Health: Implications for Women.Current atherosclerosis reports · 2022
   Review
3. Mentorship and the Leaky Pipeline in Academic Cardiology.Circulation. Cardiovascular quality and outcomes · 2022
   Article
4. Are we any WISER yet? Progress and contemporary need for smart trials to include women in coronary artery disease trials.Contemporary clinical trials · 2022
   Review
5. Why Are We Not There Yet?JACC. Case reports · 2021
   Article
6. Inflection Point: Ideas for Accelerating Breakthroughs and Improving Cardiovascular Health.Circulation. Cardiovascular quality and outcomes · 2020
   Article

Corrections and comments

• Comment on
  Representation of Women in Cardiovascular Clinical Trial Leadership.2020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as